STXS - Stereotaxis, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
3.3400
-0.0400 (-1.18%)
As of 2:43PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.3800
Open3.3100
Bid3.3000 x 4000
Ask3.3400 x 36900
Day's Range3.2600 - 3.3800
52 Week Range1.0100 - 4.7500
Volume39,007
Avg. Volume128,270
Market Cap198.469M
Beta (3Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.0980
Earnings DateNov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Stereotaxis and Catheter Precision Combine Robotic Navigation and Preoperative Arrhythmia Localization to Treat Cardiac Arrhythmias

    Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO™ arrhythmia localization and Stereotaxis’ Robotic Magnetic Navigation technologies. VIVO uses information commonly collected prior to cardiac procedures to identify the source of dangerously rapid heartbeats.

  • Could Stereotaxis, Inc.'s (NYSEMKT:STXS) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Stereotaxis, Inc.'s (NYSEMKT:STXS) Investor Composition Influence The Stock Price?

    A look at the shareholders of Stereotaxis, Inc. (NYSEMKT:STXS) can tell us which group is most powerful. Insiders...

  • GlobeNewswire

    Stereotaxis to Report Third Quarter 2019 Financial Results on November 14, 2019

    ST. LOUIS, Nov. 06, 2019 -- Stereotaxis, Inc. (NYSE American: STXS) the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today.

  • GlobeNewswire

    Stereotaxis and inHEART Combine Robotic Precision and Advanced Preoperative 3D Mapping to Treat Cardiac Arrhythmias

    Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic Magnetic Navigation technologies. The latest version of Stereotaxis software, recently cleared for use in Europe and by the FDA, utilizes a software interface that integrates inHEART’s maps, cleared for use in Europe, and allows physicians to utilize them to guide robotic cardiac ablation procedures.

  • GlobeNewswire

    Stereotaxis and ADAS 3D Combine Robotic Precision and Advanced Preoperative Substrate Mapping to Treat Cardiac Arrhythmias

    Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treated with the integration of ADAS 3D’s advanced preoperative substrate mapping and Stereotaxis’ Robotic Magnetic Navigation technologies. ADAS 3D helps identify possible sources of dangerous irregular heartbeats and provides a map to guide physicians in delivering treatment. The software uses preoperative cardiac MRI to generate detailed three-dimensional cardiac models that identify arrhythmia substrate and characterize cardiac tissue.

  • This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks
    Insider Monkey

    This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks

    DAFNA Capital Management was founded in 1999 by Dr. Nathan Fischel, who is the fund’s CEO. Dr. Fischel is Pediatric Hematologist-Oncologist with a long career in medicine. He graduated from Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. He continued his […]

  • GlobeNewswire

    Stereotaxis Announces CFO Transition

    Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019. Martin Stammer, who has served as Chief Financial Officer since 2013, has accepted a position as the CFO of a large professional services firm headquartered in the St. Louis area and will resign from the Company, effective September 30, 2019. “I have really enjoyed my time at Stereotaxis and firmly believe in the future of the Company,” said Martin Stammer.

  • GlobeNewswire

    Stereotaxis Announces Uplisting to NYSE American

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its common stock has been approved for listing on the NYSE American. The Company’s common stock will begin trading on the NYSE American exchange under its current symbol, “STXS,” at the open of trading on Sept. 6, 2019. The Company’s common stock will continue to trade on the OTCQX until the close of the market on Sept. 5, 2019.

  • Thomson Reuters StreetEvents

    Edited Transcript of STXS earnings conference call or presentation 8-Aug-19 1:00pm GMT

    Q2 2019 Stereotaxis Inc Earnings Call

  • GlobeNewswire

    Stereotaxis Reports 2019 Second Quarter Financial Results

    ST. LOUIS, Aug. 08, 2019 -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial.

  • GlobeNewswire

    Stereotaxis Announces $25 Million Private Placement

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 million private placement. In this private placement, Stereotaxis is selling approximately 12.2 million shares of common stock and convertible preferred stock at a purchase price of $2.05 per share to select healthcare-focused and growth-oriented institutional investors.

  • GlobeNewswire

    Stereotaxis to Report Second Quarter 2019 Financial Results on August 8, 2019

    ST. LOUIS, Aug. 07, 2019 -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that.

  • GlobeNewswire

    Society for Cardiac Robotic Navigation to Showcase Stereotaxis Clinical Value & Technology

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will participate in the Society for Cardiac Robotic Navigation’s 4th Annual Meeting, which will take place September 5-6 in Nice, France. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of remote technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals interested in advancing robotics to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology.

  • GlobeNewswire

    Stereotaxis Announces the First Graduating Class of the Robotic Electrophysiology Fellows Program

    Stereotaxis, Inc. (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the first graduating class from its Robotic Electrophysiology Fellows Program. The Robotic Electrophysiology Fellows Program is designed to enhance the traditional electrophysiology fellowship by facilitating mastery of robotic magnetic navigation, fostering a global community of the future leaders in the field, and providing fellows with a differentiated and specialized skillset as they advance their medical careers.

  • Thomson Reuters StreetEvents

    Edited Transcript of STXS earnings conference call or presentation 9-May-19 1:00pm GMT

    Q1 2019 Stereotaxis Inc Earnings Call

  • GlobeNewswire

    Stereotaxis Announces Next Generation Robotic Magnetic Navigation System and Imaging System

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, introduced today Stereotaxis Genesis RMN, the next-generation robotic platform and a significant advancement in robotic magnetic navigation technology. “I am excited and pleased to introduce Stereotaxis Genesis, the future of robotic electrophysiology,” said David Fischel, Chairman and CEO of Stereotaxis.

  • GlobeNewswire

    Stereotaxis and Osypka Enter Strategic Collaboration to Advance Robotic Catheter Technology

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, and Osypka AG, a pioneer in electrophysiology and leading manufacturer of interventional products, announced today a broad strategic collaboration. Stereotaxis and Osypka are designing and developing a next-generation magnetic ablation catheter to be navigated using Stereotaxis’ robotic technology.

  • GlobeNewswire

    Stereotaxis Reports 2019 First Quarter Financial & Operational Results

    ST. LOUIS, May 09, 2019 -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial.

  • GlobeNewswire

    Stereotaxis to Showcase Innovation and Technology at Heart Rhythm 2019 and Report First Quarter 2019 Financial Results on May 8-9, 2019

    The feature presentation by David Fischel, Chairman and CEO, will highlight Stereotaxis’ innovation accomplishments and strategy and will take place on Wednesday, May 8 at 5:30 p.m. Pacific Time at the Stereotaxis booth. Additional details for the conference call and webcast, which will be held on May 9 at 9:00 a.m. Eastern Time, are provided at the bottom of this release. The Stereotaxis booth will provide visitors with a hands-on experience of robotic navigation, the chance to participate in head-to-head competition using robotic simulators, and the opportunity to take a virtual reality tour through the robotic electrophysiology operating room of the future.

  • GlobeNewswire

    Stereotaxis to Highlight Latest Techniques for Performing Robotic Ablations at European Heart Rhythm Association Annual Congress March 17-19

    Stereotaxis, Inc. (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will be attending the European Heart Rhythm Association (EHRA) Annual Congress from March 17-19 in Lisbon, Portugal. “We are excited to be attending the 2019 EHRA congress in Portugal,” said David Fischel, Stereotaxis Chairman and CEO.

  • Thomson Reuters StreetEvents

    Edited Transcript of STXS earnings conference call or presentation 12-Mar-19 2:00pm GMT

    Q4 2018 Stereotaxis Inc Earnings Call

  • GlobeNewswire

    Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures

    Stereotaxis (STXS) and Acutus Medical today announced the first patients have been successfully treated utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems. The integrated technologies are cleared for use in Europe with additional regulatory clearances expected in the coming months. The integration of these advanced technologies enables physicians to clearly see a patient’s arrhythmia pattern and then reach those targets to deliver therapy with the accuracy of robotic navigation.

  • GlobeNewswire

    Stereotaxis Reports 2018 Full Year Financial Results

    Record high annual recurring revenue of $27.8 million; 3% annual growthPositive annual net income for the first time in Company history despite significantly increased R&D.

  • GlobeNewswire

    Stereotaxis to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

    ST. LOUIS, March 04, 2019 -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced.